DE60017453D1 - Transkriptionsfaktor und dessen dna - Google Patents

Transkriptionsfaktor und dessen dna

Info

Publication number
DE60017453D1
DE60017453D1 DE60017453T DE60017453T DE60017453D1 DE 60017453 D1 DE60017453 D1 DE 60017453D1 DE 60017453 T DE60017453 T DE 60017453T DE 60017453 T DE60017453 T DE 60017453T DE 60017453 D1 DE60017453 D1 DE 60017453D1
Authority
DE
Germany
Prior art keywords
present
polypeptide
dna
activity
preventives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017453T
Other languages
English (en)
Other versions
DE60017453T2 (de
Inventor
Koji Yoshimura
Yuichi Hikichi
Kenichi Noguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60017453D1 publication Critical patent/DE60017453D1/de
Publication of DE60017453T2 publication Critical patent/DE60017453T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60017453T 1999-11-26 2000-11-24 Transkriptionsfaktor und dessen dna Expired - Lifetime DE60017453T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP33647599 1999-11-26
JP33647599 1999-11-26
PCT/JP2000/008257 WO2001038392A1 (fr) 1999-11-26 2000-11-24 Nouveau facteur de transcription et son adn

Publications (2)

Publication Number Publication Date
DE60017453D1 true DE60017453D1 (de) 2005-02-17
DE60017453T2 DE60017453T2 (de) 2005-12-22

Family

ID=18299528

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017453T Expired - Lifetime DE60017453T2 (de) 1999-11-26 2000-11-24 Transkriptionsfaktor und dessen dna

Country Status (8)

Country Link
US (1) US7241860B1 (de)
EP (1) EP1233023B1 (de)
JP (1) JP2001211890A (de)
AT (1) ATE286911T1 (de)
AU (1) AU1549701A (de)
CA (1) CA2392351A1 (de)
DE (1) DE60017453T2 (de)
WO (1) WO2001038392A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05178896A (ja) * 1990-08-23 1993-07-20 Mitsubishi Kasei Corp 新規なタンパク質、それをコードする遺伝子及びその産生方法
JP3585180B2 (ja) 1993-05-11 2004-11-04 三菱化学株式会社 新規なヒトタンパク質およびそれをコードする遺伝子
US5851775A (en) * 1997-03-20 1998-12-22 Johns Hopkins University β-catenin, Tcf-4, and APC interact to prevent cancer

Also Published As

Publication number Publication date
DE60017453T2 (de) 2005-12-22
CA2392351A1 (en) 2001-05-31
EP1233023B1 (de) 2005-01-12
AU1549701A (en) 2001-06-04
JP2001211890A (ja) 2001-08-07
EP1233023A1 (de) 2002-08-21
US7241860B1 (en) 2007-07-10
EP1233023A4 (de) 2003-01-02
WO2001038392A1 (fr) 2001-05-31
ATE286911T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
DE69841850D1 (de) Differenzierung in osteoblasten der fettgewebe-stromalen zellen und ihre verwendungen
BR9810651A (pt) Certos derivados de diarilimidazol; uma nova classe de ligantes npy especìficos
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
AP0202538A0 (en) Inhibitors of interleukin -1b converting enzyme.
HK1155944A1 (en) W-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
HU9500673D0 (en) Novel rapamycin binding proteins and their diagnostic and therapeutic use
ATE253385T1 (de) Hochmineralisierte osteogene schwammzusammensetzungen und ihre verwendung
IL143266A0 (en) Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
IL136768A0 (en) INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
DE69837809D1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE69819360D1 (de) Neue psoralene zur inaktivierung von pathogenen
ZA9810735B (en) Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use
WO1999037604A3 (en) Dialkyl ureas as calcitonin mimetics
WO1999053040A3 (de) Menschliche nukleinsäuresequenzen aus ovartumorgewebe
BR9711795A (pt) Peptìdeos tendo propriedades antiproliferativas
Hannallah et al. Gene therapy in orthopaedic surgery
WO2001042243A3 (en) Protein kinase inhibitors
ATE286911T1 (de) Transkriptionsfaktor und dessen dna
ATE266396T1 (de) Zubereitung und verwendung von rar antagonisten zur forderung der chondrogenese
ATE533781T1 (de) Heparin-bindungsstelle enthaltendes knochenmorphogenetisches protein 6 und osteogene vorrichtungen und pharmazeutische produkte, die diese enthalten
AU2001235696A1 (en) Compositions useful for regulating parkin gene activity

Legal Events

Date Code Title Description
8364 No opposition during term of opposition